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Abstract
We evaluate the accuracy of varying thermal
expansion models for the quasi-harmonic
approximation (QHA) relative to molecular
dynamics (MD) for 10 sets of enantiotropic
organic polymorphs. Relative to experi-
ment we find that MD, using an off-the-
shelf point charge potential gets the sign
of the enthalpic contributions correct for
6 of the 10 pairs of polymorphs and the
sign of the entropic contributions correct for
all pairs. We find that anisotropic QHA
provides little improvement to the error in
free energy differences from MD relative to
isotropic QHA, but does a better job cap-
turing the thermal expansion of the crystals.
A form of entropy–enthalpy compensation
allows the free energy differences of QHA to
deviate less than 0.1 kcal/mol from MD for
most polymorphic pairs, despite errors up to
0.4 kcal/mol in the entropy and enthalpy.
Deviations in the free energy of QHA and
MD do not clearly correlate with molecu-
lar flexibility, clarifying a previously pub-
lished finding. Much of the error previously
found between QHA and MD for these flex-
ible molecules is reduced when QHA is run
from a lattice minimum consistent with the
same basin as MD, rather than the energy-
minimized experimental crystal structure.
Specifically, performing anisotropic QHA
on lattice minimum quenched from low-
temperature replica exchange simulations
reduced the error previously found by 0.2
kcal/mol on average. However, these con-
formationally flexible molecules can have
many low-temperature conformational min-
ima, and the choice of an inconsistent min-
ima causes free energies estimated from
QHA to deviate from MD at temperatures
as low as 10 K. We also find finite size er-
rors in the polymorph free energy differ-
ences using anisotropic QHA, with free en-
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ergy differences as large as 0.5 kcal/mol be-
tween unit and supercells loosely correlated
with differences in anisotropic thermal ex-
pansion. These larger system sizes are com-
putationally more accessible because our
cheaper 1D variant of anisotropic QHA,
which gives free energies within within 0.02
kcal/mol of the fully anisotropic approach
at all temperature studied. The errors be-
tween MD and experiment are 1–2 orders of
magnitude larger than those seen between
QHA and MD, so the quality of the force
field used is still of primary concern, but
this study illustrates a number of other im-
portant factors that must be considered to
obtain quantitative organic crystal thermo-
dynamics.
Introduction
Solid organics can pack stably in multi-
ple forms, each of which can have sig-
nificantly different chemical and materials
properties from each other. The ability of a
molecule to arrange in multiple solid forms,
or polymorphs, can change crystal solu-
bility,1,2 charge mobility,3,4 hardness,5 and
reactivity.6–8 Relative stability of crystals
can change with temperature2,9–19 and pres-
sure,20–23 so we must consider entropic ef-
fects and crystal lattice changes when mod-
eling the crystal thermodynamics.
Methods such as molecular dynamics
(MD) and the quasi-harmonic approxima-
tion (QHA) are important for understand-
ing the relative stability of crystals. QHA
estimates the thermodynamics as a func-
tion of temperature and pressure by com-
puting free energy due to harmonic vibra-
tions around each crystal lattice minimum,
and then determining the lattice geome-
try that minimizes the Gibbs free energy
at each temperature as the crystal is ex-
panded from the initial crystal lattice min-
imum. It is common to model thermal ex-
pansion isotropically, where the lattice vec-
tors remain proportional and angles fixed.
MD provides a more accurate description
of the entropy and therefore free energy by
generating the full conformational ensemble
of the crystal, rather than neglecting anhar-
monic motions. Additionally, QHA assumes
a single lattice is representative of the crys-
tal at low temperatures whereas MD sam-
ples an ensemble of lattice configurations.
Our previous studies show that an
isotropic QHA model can often yield free
energy differences between polymorphs that
fall within numerical error of the polymorph
free energy differences computed by MD for
small and rigid molecules. However, free en-
ergies from QHA deviates from those gen-
erated by MD by > 0.1 kcal/mol at 300 K
for dynamically disordered crystals or crys-
tals with greater conformational flexibil-
ity.24 The small-molecule crystals examined
in our previous study all showed some level
of anisotropic expansion, and the error in
the QHA free energy qualitatively increased
with the degree of anisotropy. We concluded
that the deviations of the isotropic QHA
from MD were either due to 1) an inaccurate
thermal expansion model or 2) anharmonic
motions in the crystal lattice, or 3) some
combination of the two. Without modeling
QHA anisotropically, we could not defini-
tively determine the source of the deviations
of QHA from MD.
We recently developed a method to ef-
ficiently determine the true anisotropic free
energy minimum within the quasi-harmonic
framework.25 This method relies on deter-
mining gradient of the lattice parameters
with respect to temperature. Our gradi-
ent approach identifies high temperature
free energy minimum that are 0.01–0.23
kcal/mol lower than the minimum identi-
fied with an isotropic model, altering the
polymorph free energy differences of pirac-
2
etam and resorcinol by 0.02–0.12 kcal/mol
for unit cells of 4–8 molecules.25 Our fully
anisotropic approach and even a simplified
1D-anisotropic approach outperformed the
accuracy of current quasi-anisotropic meth-
ods that only consider the anisotropy due to
the potential energy as a function of crystal
lattice vectors.26–30
In this paper we re-evaluate the 10 of
the 12 polymorph pairs previously studied
with MD and isotropic QHA to determine
whether an anisotropic thermal expansion
model can improve the performance of QHA
relative to MD.25 Specifically, we:
• evaluate the use of an off-the-shelf
point charge potential in modeling the
entropy, enthalpy, stability, and ther-
mal expansion of organic polymorphs;
• determine how well our 1D-QHA vari-
ant compares to QHA using full
anisotropic expansion over a larger
data set than our initial anisotropic
methods paper;25
• determine if finite size effects signif-
icantly contribute to the free energy
ranking of polymorphs;
• discuss the appropriate ways to com-
pare QHA and MD;
• determine if anisotropic QHA can re-
duce errors with respect to MD found
previously with isotropic QHA;
• evaluate if entropy–enthalpy compen-
sation plays a significant role in differ-
ences between QHA and MD; and
• highlight crystal behaviors found in
MD that QHA cannot account for.
Methods
In this study we examine the experimen-
tally known polymorphs of the 10 molecules
shown in Figure 1 using QHA and MD. All
10 of these molecules were examined in our
previous study.24 Most MD results in this
study are from our previous publication,24
and a methodological discussion of MD can
be found there.24,31 Modifications of the MD
procedure and where these modified simula-
tions are used will be discussed in the con-
text of the paper. All isotropic QHA re-
sults have been updated from that previous
study and we describe those changes made
here. In our previous study we examined
12 enantiotropic pairs of polymorphs, but
have excluded two molecules due to the ex-
perimentally known plastic phases with dy-
namic disorder at each molecular site. The
dynamic disorder was confirmed with MD,
both by others and ourselves, for the rota-
tion of cyclopentane15,24 and trans/gauche
isomerization of succinonitrile24,32 in the
disordered crystals. This behavior is in-
herently anharmonic, meaning there is no
chance that QHA can properly model them,
and hence they are left out of this study.
Furthermore, both plastic phase crystals
had their lattices constrained for stability
in MD in previous studies,24 so they were
not modeling fully anisotropic thermal ex-
pansion.
Quasi-Harmonic Approxima-
tion
In the quasi-harmonic approximation
(QHA) the Gibbs free energy is computed
by determining the lattice geometry that
minimizes the sum of the potential and the
energy of the static, harmonic lattice vibra-
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Figure 1: Molecules examined in this study.
tions, as shown in eq 2.
G(T ) = min
y
f(y, T ) (1)
f(y, T ) = min
x
(U(y,x))
+Av(y, T ) + PV (2)
y = V,C, λ
where T is the temperature, P is the pres-
sure, minx (U(y,x)) is the lattice energy of
the minimum energy cell geometry y and ge-
ometry optimized lattice coordinates x, and
Av is the Helmholtz vibrational free energy
of a harmonic oscillator. We define the cell
geometry as y, which for isotropic expan-
sion is the volume V , anisotropically with
the six dimensional lattice tensor C, or us-
ing our modified 1D-anisotropic expansion
defined by λ.
The Helmholtz free energy (Av) of the
lattice harmonic vibrations contribute to
the entropic portion of QHA. We use the
classical version of Av for comparison to
MD, shown in eq 3.
Av(V, T ) =
∑
k
β−1 ln (βh¯ωk(V )) (3)
where β is (kBT )
−1, h¯ is the reduced Planck
constant, and ωk is the frequency of the
phonon of the kth vibrational mode of the
crystal lattice.
Gru¨neisen Parameters
There are two common methods within the
QHA framework to estimate the phonon fre-
quencies of the crystal lattice at each lattice
geometry of interest. The first way is to
compute and diagonalize the mass-weighted
Hessian of every crystal structure, which is
computationally demanding. The second
way is to use the Gru¨neisen parameter ap-
proach assumes that the changes in the fre-
quencies of a particular phonon are constant
as the crystal is strained in a particular di-
rection. Use of the Gru¨neisen parameter
to calculate the thermodynamics of organic
and inorganic material is common.24,33–36
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This assumption can introduce errors, but
we have shown for polymorph free energy
differences that those errors are generally
less than 0.02 kcal/mol.25 This is smaller
than the experimental error in most cases,
so we will exclusively use the Gru¨neisen pa-
rameter approach for QHA calculations in
this paper when calculating polymorph free
energy differences.
The standard definition of the Gru¨neisen
due to a volume change is in eq 4, which is
directly applicable only for constant strains,
such as isotropic expansion, is:
γk = − V
ωk
∂ωk
∂V
(4)
where γk is the Gru¨neisen parameter for the
kth vibrational frequency. Eq 4 is solved nu-
merically, which requires diagonalization of
the mass-weighted Hessian at two volumes
to produce reference frequencies. The corre-
sponding Gru¨neisen parameters can be used
to solve the frequencies at all isotropic vol-
umes relative to a reference point, generally
the lattice minimum structure.
The Gru¨neisen parameter for the vol-
ume can be extended to a crystal placed
under any strain,25,37 which we will use
for anisotropic expansion. Eq 5 is the
anisotropic version of the isotropic equa-
tion(eq 4).
γk,i = − 1
ωk
∂ωk
∂ηi
∣∣∣∣
ηj 6=ηi
(5)
Here, the Gru¨neisen parameter for the kth
vibrational mode due to the ith strain (ηi)
applied to the crystal is γk,i. The symmet-
ric 3×3 strain matrix η allows us to com-
pute 6 sets of Gru¨neisen parameters nu-
merically. With the Gru¨neisen parameters
and reference frequencies, we can compute
the frequencies of the lattice parameters at
any cell geometry of interest, by integrating
eq 5. A full discussion of the use of both the
isotropic and anisotropic Gru¨neisen param-
eters can be found in previous work.25
Thermal Expansion
We previously implemented a method to de-
termine the crystals thermal expansion,25
which can be used to solve bi-optimization
problems,38 such as QHA. Eq 6 gives the
general formulation for determining the
crystal thermal expansion. If we have a
reference structure, the 0 K minimum (i.e.
classical lattice minimum), we can compute
the thermal expansion and numerically in-
tegrate with temperature.
∂y
∂T
=
(
∂2G
∂y2
)−1
∂S
∂y
(6)
y = V, λ,C
In eq 6, T is the temperature, S is the en-
tropy, and G is the Gibbs free energy. By
computing the numerical derivatives of the
entropy and Gibbs free energy we can de-
termine the gradient of y, the cell geometry,
with respect to temperature.
Isotropic Expansion
Isotropic expansion assumes that the lattice
vectors remain proportional to one another
and the lattice angles remain fixed. Due
to these constraints the solution to QHA in
eq 2 requires minimization of a single vari-
able, the volume (y = V ). We compute
the rate of isotropic thermal expansion us-
ing eq 6 and replacing y with the crystal
volume (V ).
Anisotropic Expansion
Anisotropic expansion allows the crystal lat-
tice to relax to the harmonic free energy
minimum structure by removing all con-
straints in isotropic expansion. In eq 2 we
minimize the free energy as a function of
all six crystal lattice parameters (y = C),
which makes the problem of minimizing the
5
Gibbs free energy for QHA more complex.
We compute the thermal expansion for all
six parameters by using eq 6 and replacing
y with a array of the six lattice parameters
(C).
1D-Anisotropic Expansion
Computing eq 6 for anisotropic expansion
(C) requires 73 lattice optimizations to de-
termine a single six-dimensional gradient,
which becomes increasingly expensive to
compute for the entire temperature range of
interest. In our previous work,25 we found
if the ratio of anisotropic expansion was
kept constant at all temperatures we could
achieve the same free energy differences
within 0.005 kcal/mol of full anisotropic ex-
pansion. In that paper, we presented eq 7,
Ci(λ) = Ci(λ = 0) + κiλ(T ) (7)
where the lattice parameter Ci is a function
of the variable λ and κi. In this case, λ is
a single parameter describing the expansion
in eq 2, which is zero at the 0 K lattice min-
imum value of Ci. κi is the gradient com-
puted in eq 6 for y = C at 0 K.
Molecular Dynamics
A more complete approach to compute the
thermodynamics of the crystals, including
the free energy difference between poly-
morphs, is molecular dynamics (MD), which
generates (in theory) the full configurational
ensemble at a given temperature of inter-
est. For our method, there are two nec-
essary steps for computing the free energy
differences of polymorphs using MD: 1) de-
termine ∆G between polymorphs at a refer-
ence temperature with simulations of a se-
ries of non-physical intermediate states and
2) determine ∆G as a function of temper-
ature for each polymorph using simulations
at range of temperatures. For the first step,
we can drive each crystal along a reversible
thermodynamic path to an ideal gas state
by turning off intermolecular energies to
determine the reference free energy differ-
ences. Then, with simulations at intermedi-
ate temperatures we can relate each temper-
ature point back to the reference energy dif-
ference between polymorphs using the Mul-
tistate Bennett Acceptance Ratio (MBAR).
A full discussion of this approach can be
found in our previous work.24,31
Computational Details
We have provided as supporting infor-
mation a .zip file including all computa-
tional details to re-run simulations for both
MD and QHA. For specifications on how
we chose certain parameters we refer the
reader back to our previous publications
that present the methods for MD24,31 and
QHA.25
Molecular Dynamics
For a number of crystals, we found that
the lattice parameters from the previous
study24 did not continuously change with
temperature at low T for MD, so we re-
ran the crystals with temperature replica
exchange (REMD) to better escape from
metastable states and thus allow for bet-
ter convergence to the 0 K lattice energy
minimum. Replica exchange parameters
were chosen to give an average exchange
probability of ∼ 0.3 between temperature
samples from 10 K up to 350 K. Tempera-
ture replica exchange allows the simulations
at different temperatures to exchange with
one another, which causes the crystal to be
heated up and reannealed throughout simu-
lation while maintaining the proper ensem-
ble distribution at all temperatures.39 Tem-
perature replica exchange was required to
compute the low-temperature ensembles of
for tolbutamide, chlorpropamide, and arip-
iprazole. We provide input files for both
MD and QHA all within the input files.zip,
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which contains all parameters for individual
crystals and simulation settings for GRO-
MACS 2018.
Quasi-Harmonic Approximation
All QHA calculations were performed us-
ing our Python based lattice dynam-
ics code available on GitHub at http:
//github.com/shirtsgroup/Lattice_
dynamics. The code currently wraps
around a number of molecular modeling
packages. In this paper, all lattice vibra-
tions, energy evaluations, and optimizations
were performed using Tinker 8.1 molecular
modeling distributed TINKER code to cor-
rect for errors in the Hessian calculation.
Those modifications are discussed in the
main paper and supporting information of
our previous work and have since been up-
dated in Tinker 8.7.25
Lattice structures were retrieved from
the Cambridge Crystallographic Data
Center (https://www.ccdc.cam.ac.uk/
structures/) and a unit and supercell were
lattice optimized. Supercells were created
assuring that the three lattice vectors were
twice the van der Waals cutoff, (8 A˚). Spec-
ifications on cell size can be found in the
Table S3. Each molecule was parameter-
ized using the OPLS-AA40,41 classical fixed
point charge potential:
Utotal = Ubond + Uangle + Udihedral
+Uvdw + Ucoulombic (8)
where the exact forms of the each of the en-
ergy terms are defined in the references.
The crystal structures were geometry
and lattice optimized to the lattice mini-
mum structure. Optimization of the crys-
tal structure was performed with Tin-
ker’s xtalmin executable to an RMS gra-
dient/atom of 10−5. The molecules centers
of mass, keeping the coordinates relative to
the center of mass constant constant. The
crystal was then geometry optimized using
Tinker’s minimize executable to an RMS
gradient/atom of 10−4. These values were
chosen to maximize convergence and numer-
ical stability for the gradient method, and
this choice is discussed fully in the support-
ing information of our previous work.25
To determine y(T ) across the entire tem-
perature range we use a 4th order Runge-
Kutta integrator using the thermal gradi-
ent approach to satisfy eq 1. For most crys-
tals, we found that 3 steps of 100 K each
up to 300 K ensures that the crystal was at
a locally metastable free energy minimum
at all temperatures. If the structure is not
at a free energy minimum with respect to
box geometry variables at 300 K, the struc-
ture was re-run with 6 Runge-Kutta steps.
For the unit cells only, if 6 steps could not
maintain the crystal at a free energy min-
imum then 20 steps were run. All results
shown are for the maximum temperature
step that could be achieved while assuring
that it remained at a free energy minimum
with respect to box geometry under expan-
sion (temperatures given in Table S4). Re-
sults for the graphed intermediate points
between Runge-Kutta steps were calculated
with a third order spline that was fit to the
lattice parameters with temperature.25,42
Details of experimental data
used for comparison
We have exhaustively collected experimen-
tal results reported in literature to com-
pare thermal expansion and thermodynamic
stability to for MD. In previous work
we compared entropic and enthalpic con-
tributions to polymorph relative stabili-
ties, but have found some inconsistencies
in those reported results24 and reevalu-
ate these calculations here. Provided with
our supporting information are two files,
experimental expansion.csv and experimen-
7
tal stability.csv, containing the literature
results we used for comparison. In the
expansion results file we provide the re-
ported experimental lattice parameters, ci-
tation references and links, reported tem-
peratures, and reference codes if the struc-
ture was submitted to the CCDC. For the
stability results we report the values seen in
Figure 2 along with the reported tempera-
tures and literature references.
Results and Discussion
The approaches presented above allow us to
evaluate the effectiveness of QHA methods
with different treatments of thermal expan-
sion relative to MD for polymorph thermo-
dynamics, including free energy differences
between polymorphs, and lattice expansion.
The differences between approaches for es-
timating the temperature dependence are
greatest at high temperatures, so all com-
parisons are shown at the maximum tem-
perature at which QHA is stable.
For QHA, we found that discontinuous
readjustment of the molecules within the
lattice occurs frequently during expansion,
causing the method to expand to a struc-
ture that no longer corresponds with free
energy minimum of the chosen expansion
variable. As the crystal expands, the free
volume around the molecules increases, al-
lowing molecules to readjust into alternate
minima more favorable to the lattice energy
than the minima found by continuous defor-
mation of lower temperature minima. These
structural disruptions are problematic for
the numerical stability of the gradient ap-
proach and generally cause the crystal to ex-
pand to a structure that is not a free energy
minimum. For example, upon expansion of
tolbutamide, at a certain point the alkyl tail
can move into a newly created free volume,
causing the quasi-harmonic free energy to
become discontinuous with temperature.
We determine if the crystal is at a free
energy minimum with respect to the geom-
etry parameter y by checking if:(
∂G
∂y
)
Backward
< 0 <
(
∂G
∂y
)
Forward
(9)
If our crystal is at or near a free energy min-
imum, then the forward and backward nu-
merical solution to eq 9 must be positive
and negative respectively. If both are the
same sign, then we must no longer be at a
minimum.
All results using QHA are shown at
the maximum temperature (Tmax), which
is the highest temperature to satisfy eq 9.
The values of Tmax are reported in Ta-
ble S4 and Table S5. Plots of the poly-
morph free energy differences and lattice
expansions versus temperature for the 10
molecules studied are provided (Figures S20
– S56). Further quantification of the numer-
ical and structural instability is discussed in
the work where we initially presented the
gradient method.25
Comparisons to Experimental
Results
We found that the OPLS-AA point charge
potential is a poor predictor of the sign of
enthalpic differences for polymorphs rela-
tive to experiment, as is expected for the
simplicity of the energy function, but does
accurately estimate the sign of the entropic
differences. In Figure 2a and 2b the en-
thalpic and entropic contributions to the
polymorph free energy differences at 300 K
for the supercells using MD are shown rela-
tive to their experimental values, which are
reported at varying temperatures that gen-
erally corresponding with the polymorph
transition temperature.2,9,10,14,16,18,43–46 The
sign of the enthalpic contributions is only
8
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Figure 2: 300 K polymorph differences from MD for a) enthalpy and b) entropy versus exper-
imental values taken from literature.2,9,10,14,16,18,43–46 The sign of the enthalpy is only correct
for MD for 6 of the 10 molecules, with no clear distinguishing molecular or crystallographic
features separating the crystals with the incorrect sign. This contrasts with the entropy,
which is correct in sign for all 10 molecules. If the polymorph pairs fall in the green quad-
rants than MD has the same sign as experiment, and the wrong sign in the red quadrants.
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correct for 6 of the 10 polymorph pairs.
The 4 molecules where the simulation has
the wrong enthalpic ranking are pirac-
etam, pyrazinamide, resorcinol, and parac-
etamol, and none of the enthalpic errors in
these molecules have obvious correlations to
chemical groups present, flexibility, crystal
Z and Z’ values, or relative packing. This
contrasts with the polymorph entropy dif-
ferences, where the sign is correct for MD for
all 10 molecules. The RMSD between the-
ory and experiment are 4.0 and 2.0 kcal/mol
for ∆H and T∆S, respectively. The most
likely large sources of deviation from exper-
iment could be due to 1) the experimental
values coming from the polymorph transi-
tion temperature, not 300 K and 2) the use
of a point charge potential to model the
crystal energetics.
The lattice geometries for MD differ
moderately from experiment, though the
volumes match experiment more closely.
We can quantitatively compare to experi-
ment using exhaustive experimental results
from Brandenburg and Wilson for carba-
mazepine form III and paracetamol form I,
respectively.47,48 The expansion of the lat-
tice vectors, angles, and volume are shown
for carbamazepine form III (Figure 3) and
paracetamol form I (Figure 4). Prediction
accuracy of lattice vectors varies both with
crystal and lattice vector. We find that if
the lattice vectors are orthogonal for exper-
iment, MD always gets the corresponding
angle correct or within error as seen with α
and β angles for carbamazepine and parac-
etamol. Despite errors in the individual lat-
tice parameters, the crystal volume is sim-
ilar between MD and experimental values.
In the case of paracetamol (Figure 4) the
experimental volume is within error of MD.
The change in the lattice vectors and or-
thogonal angles in MD generally agrees with
experiment despite errors in the actual ge-
ometry. In Figures 3 and 4 we provide the
thermal expansion of each parameter by fit-
ting a linear fit to MD and experimental
data at all temperatures. In carbamazepine
the change in the slope of experimental lat-
tice parameters at low temperatures could
be indicative of quantum behavior from the
zero point energy, so for this crystal we per-
form the linear fit on values above 100 K.
For all of the lattice vectors we see that
the thermal expansion between MD and ex-
periment are the same order of magnitude
and sign. For the orthogonal angles there is
no expansion. However, the thermal expan-
sion of the β angle in both polymorphs has
the wrong sign and in the case of paraceta-
mol form I is an order of magnitude differ-
ent. For carbamazepine, we see larger diver-
gence between experiment and MD at low
temperatures (T < 100 K), which would be
indicative of quantum zero-point energy ef-
fects. For both polymorphs there is also
good agreement with experiment for the
volumetric thermal expansion. Accurately
modeled thermal expansion helps to explain
why we also get the correct sign of the en-
tropic differences for all 10 polymorph pairs
in Figure 2b.
Testing the Validity of 1D-
Anisotropic QHA
Anisotropic expansion is relatively ex-
pensive compared to isotropic expansion,
though still 2 orders of magnitude cheaper
than free energy estimation with MD. Our
previous work shows that a 1D-variant of
anisotropic expansion can be a sufficient
substitute to speed up the method with
little effect on the accuracy of computed
free energy differences.25 Fully anisotropic
expansion requires 73 structure optimiza-
tions every time the thermal gradient is
computed. This contrasts with the 1D-
approach, which requires the initial 73 op-
10
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Figure 3: Thermal expansion of carbamazepine form III comparing MD to experimental
results provided in literature.47,49–53 While the lattice parameters differ between theory and
experiment, the thermal expansion is similar between MD and experiment for all lattice pa-
rameters and volume. At low temperatures we find the largest deviation between experiment
and MD. The shaded green area is the standard deviation in the lattice parameter during
the MD simulation.
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Figure 4: Thermal expansion of paracetamol form I comparing MD to experimental results
provided in literature.48,54–56 While the lattice parameters differ between theory and experi-
ment, the thermal expansion is similar between MD and experiment for all lattice parameters
and volume, except for the β angle. The shaded green area is the standard deviation in the
lattice parameter during the MD simulation.
timizations at 0 K followed by 3 optimiza-
tions at all subsequent points for numerical
integration. When we first presented the
gradient approach we found that the 1D-
anisotropic QHA approach computed poly-
morph free energy differences within 0.01
kcal/mol of full anisotropic expansion for
the two sets of polymorphs tested. For this
study, we ran both 1D-QHA and anisotropic
QHA on unit cells of the quenched experi-
mental structures (independent of MD) to
evaluate the effectiveness of the 1D con-
straint.
The constraints applied to 1D-
anisotropic approach provide numerical sta-
bility, allowing eq 9 to be satisfied at 300
K more frequently. At each integration
step for expansion our program checks if
eq 9 is satisfied, verifying if the crystal is
at a free energy minimum. We will only
report result up to the temperature (Tmax)
where eq 9 is satisfied. When using fully
anisotropic expansion, only 11 of the 20
crystals were able to satisfy eq 9 at all tem-
peratures (Tmax = 300 K). This contrasts
with the 1D-approach, where 19 of the 20
crystals remained at a free energy minimum
up to 300 K. The only molecules where the
fully anisotropic approach remained at a
free energy minimum for both polymorphs
were the relatively rigid resorcinol, adenine,
and carbamazepine, suggesting that rigid
molecules are less likely to experience nu-
merical disruptions in QHA.
For the 10 molecules in this study, the
RMSD in polymorph free energy difference
between 1D-anisotropic and anisotropic
QHA is 0.0066 kcal/mol, which is well below
physically meaningful sensitivity thresh-
olds. Figure 5a shows the polymorph free
energy differences computed with 1D-QHA
versus those computed with anisotropic
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Figure 5: Comparison of the results of 1D- and fully-anisotropic QHA applied to the polymor-
phic unit cells. In all plots, the filled-in markers are the molecules with multiple molecular
conformers (tolbutamide, chlorpropamide, and aripiprazole). a) Polymorph free energy dif-
ferences (∆G(Tmax)) computed with 1D and full anisotropic approaches are nearly equal.
The black line is plotted as y = x and the data has a RMSD = 0.0066 kcal/mol relative to
that line. b) The percent expansion from 0 K to Tmax for the three lattice vectors and angles
are plotted. The RMSD in percent expansion between 1D and anisotropic QHA is 0.29%.
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QHA at Tmax. The free energies of most
polymorphic pairs vary by less than 0.010
kcal/mol between 1D-QHA and anisotropic
QHA. The only exception is aripiprazole,
where the two QHA methods for determin-
ing ∆G between polymorphs differ by 0.016
kcal/mol. The error in aripiprazole comes
primarily from form X. The error in the
individual free energies of polymorphs be-
tween 1D and fully anisotropic QHA is <
0.006 kcal/mol (excluding aripiprazole form
X), whereas the error in isotropic expansion
is between 0.01–0.21 kcal/mol (Figure S11).
Similarly, the high temperature lattice ge-
ometries of the two approaches have an
RMSD of 0.29% for the expansion relative
to lattice minimum structure.
For the molecules studied, 1D-
anisotropic QHA is thus a sufficiently ac-
curate approach to model anisotropic ex-
pansion for most purposes, and is much
more efficient. The 1D approach produces
polymorph free energy differences within
0.02 kcal/mol of the fully anisotropic ap-
proach at about 10% of the computational
cost. More importantly, the 1D approach
has greater numerical stability than full
anisotropic expansion, allowing us obtain
results at higher temperatures. The close
numerical agreement between the 1D and
fully anisotropic approach up to Tmax shows
that the 1D approach is a realistic con-
straint for these molecules. We will there-
fore use the 1D approach for all further
evaluations for anisotropic QHA.
The Cell Size Has a Non-
negligible Effect on Polymorph
Stability
We observe differences in the quasi-
harmonic free energy differences between
unit cells and supercells ranging from 0.04–
0.5 kcal/mol and are loosely correlated to
differences in the high temperature cell ge-
ometry. In our previous study we assumed
that an energy contribution less than 0.12
kcal/mol would give us 90% confidence that
a re-ranking in crystal stability would not
occur,24 a number based on a previous
much larger study of lattice energies versus
quasi-harmonic free energies.57 Six of the
ten polymorphic pairs in Figure 6 exceed
that cutoff, showing that finite size errors
are sufficiently large to affect the stability
ranking of polymorphs. All unit cells were
quenched from the experimental crystals
prior to running QHA and the supercells
were constructed from the quenched unit
cells. These results used the 1D-anisotropic
approach for QHA.
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Figure 6: Differences between 1D-QHA in
unit and supercells are shown for polymorph
free energy differences against the average
RMSD in percent expansion at Tmax. There
is a moderate (R2 = 0.79) correlation be-
tween the difference in unit and supercell
percent expansion and the finite size error
in free energy. The grey line is the 0.12
kcal/mol threshold, where values below the
line have a 90% estimated confidence that
re-ranking in crystal stability would not oc-
cur.57 In all plots, the filled-in markers are
the molecules with multiple molecular con-
formers (tolbutamide, chlorpropamide, and
aripiprazole).
The error in the free energy differences
between unit and supercells is correlated to
the difference in expansion of the lattice pa-
rameters between unit and supercells. In
Figure 6 we plot the deviations in the poly-
morph free energy differences versus the av-
erage RMSD of the percent expansions in
both crystals. We found that there was
a moderate linear correlation (R2 = 0.79)
between percent expansion and deviations
in the free energy due to finite size effects.
Tolbutamide and chlorpropamide (filled-in
markers) still fall under the cutoff suggest-
ing, though with a limited data set, that
there is not necessarily significant correla-
tion between molecular flexibility and finite
size error. The largest error (0.47 kcal/mol)
is for paracetamol where the supercell is
only 6 times the size of the unit cell. This is
the smallest difference between unit and su-
per cell used in this study, with the largest
being 24 times. Furthermore, we looked at
the correlation between finite size errors and
the ratio of unit and super cell and find that
there is no correlation (R2 = 0.109 in Fig-
ure S13). The cell dimensions of supercells
relative to unit cells can be found in Table
S3.
Peforming QHA with a Lattice
Minima Consistent with MD
Ensembles
The lattice minimum structure quenched
from experiment does not always coincide
with the low temperature structures found
from MD simulation of the same model,
raising the question of what it means to
compare QHA to MD. For some of the
polymorphs studied here, we have found
that the crystal supercells clearly reorga-
nized into different configurational ensem-
bles when heated up to 300 K using MD and
can be quenched to a number of lattice min-
imum.24,58 This suggests than QHA can be
performed either independent or dependent
of MD equilibration. QHA independent of
MD equilibration, using a minimized exper-
imental structure, has the potential risk of
occupying a different basin than the MD
simulation does, leading to potentially large
differences in both lattice energy and config-
urational entropy between the approaches.
In contrast, if QHA is run from a thermally
annealed structure of the MD simulations,
we have a better chance of matching the
high-temperature MD ensemble with QHA,
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as the lattice energy and vibrational modes
will be more nearly the same, giving a purer
test of whether the high temperature behav-
ior is indeed quasi-harmonic.
To maximize the chance that we can
identify the free energy minimum at low
temperature, we performed temperature
replica exchange molecular dynamics for
the polymorphs of tolbutamide, chlor-
propamide, and aripiprazole. For these
six polymorphs, five frames from the equi-
librated 10 K REMD simulation were
quenched in order to find a lattice mini-
mum for QHA consistent with the MD en-
semble. All frames from the MD trajec-
tory quenched to minima that had their
potential energy within 0.02 kcal/mol, lat-
tice vectors within 0.2 A˚, and angles within
1.0° from one another. Differences in min-
ima arose from conformations of the alkyl
tails in both polymorphs of tolbutamide and
chlorpropamide form V. In Table 1 we re-
port the potential energy of the polymorphs
when quenched from experiment, the lat-
tice minimum used in our 2017 paper,24 and
the lowest energy structure quenched from
REMD, relative to minimum found using
REMD. Quenching from REMD produces
the lowest lattice energy structure for all
polymorphs. Overlaid structures of restruc-
tured crystals are provided in Figures S14–
S19.
When the lowest lattice energy mini-
mum is chosen, the error between isotropic
QHA and MD is reduced by 0.083 kcal/mol
from the error previously reported.24 The
error previously reported for these three sys-
tems was 0.083 – 0.397 kcal/mol, but with
the new minima is 0.014 – 0.247 kcal/mol.
In Table 2 the error of QHA for polymorph
free energy differences relative to MD us-
ing replica exchange is shown at Tmax for
the minimum found from our previous study
and the minimum quenched from the 10 K
REMD simulation. We exclude the lattice
minimum quenched from the experimental
structure since the lattice energy differences
are so large. For isotropic QHA, the min-
imum quenched from REMD reduces the
error relative to MD by 0.15 kcal/mol for
tolbutamide and chlorpropamide. We see
an increase in the error for aripiprazole,
which is minimal compared to the reduc-
tion in error for the other two sets of poly-
morphs.
When using the lower lattice energy
minimum, anisotropic QHA determines the
stability of chlorpropamide and aripipra-
zole within 0.05 kcal/mol relative to MD.
The error in QHA for tolbutamide, 0.206
kcal/mol, is still large, but is half the mag-
nitude of what was previously reported.24
Despite the new minimum of aripiprazole
producing higher error in isotropic QHA,
using anisotropic expansion reduced the er-
ror to 0.045 kcal/mol, implying that an
isotropic constraint is inappropriate. The
small increase in error when switching
to anisotropic treatments seen in chlor-
propamide for anisotropic QHA is most
likely due to cancellation of error between
polymorphs. For these polymorphs, all fur-
ther analysis of QHA will be shown for the
restructured crystals found from quenching
low-temperatures replicas of REMD simula-
tions.
Comparison of thermal expan-
sion and thermodynamics using
QHA and MD
Anisotropic QHA allows the crystal lat-
tice to relax into geometries that are more
similar to MD, but there are still persis-
tent errors in the high temperature geome-
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Figure 7: Scatter plots of the percent expansion of QHA versus MD for the lattice a) vectors
and b) angles for isotropic and 1D-anisotropic QHA lattice parameters. The RMSD to MD
is marginally improved for the lattice vectors and not improved for the angles when using
anisotropic expansion over isotropic expansion. A least square fit between MD anisotropic
QHA shows that anisotropic expansion provides a better y = x fit (black line) to MD than
isotropic expansion. The slopes for anisotropic and isotropic expansion are a) 0.89±0.22
and 0.02±0.06 and b) 0.60±0.14 and 0.0 (exact), respectively. In all plots, the filled-in
markers are the molecules with significant internal conformational freedom (tolbutamide,
chlorpropamide, and aripiprazole).
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Table 1: Potential Energy of Lattice Minimum Relative to 10 K REMD Quenched Structure
Tolbutamide Chlorpropamide Aripiprazole
I II I V I X
∆UExp.
a 1.837 0.250 0.000 3.095 1.989 0.302
∆UPrevious
b 0.442 0.250 0.000 0.294 0.048 0.000
∆UREMD 0.000 0.000 0.000 0.000 0.000 0.000
a Potential energy differences of the lattice minimum quenched from the experimental
structure and quenched from a 10 K REMD simulation; b Potential energy difference of the
lattice minimum quenched from the restructured crystal found in our previous study24 and
quenched from a 10 K REMD simulation.
Table 2: Error of QHA Relative to MD at Tmax Previously Reported
24 and Using a Lattice
Minimum Quenched from REMD
Tolbutamide Chlorpropamide Aripiprazole
QHA Iso. Aniso. Iso. Aniso. Iso. Aniso.
δ(∆GPrev.)
c 0.397 – 0.159 – 0.083 –
δ(∆GREMD)
d 0.247 0.206 0.014 0.033 0.128 0.045
c Error between QHA and MD using the lattice minimum in our previous study;24 d Error
between QHA and MD using the lattice minimum quenched from the 10 K replica of
REMD.
tries computed with QHA. In Figure 7a
and Figure 7b we show the percent ex-
pansion of QHA lattice vectors and angles
against MD, respectively. The black line
represents a perfect agreement between the
QHA method and MD, while the dashed
lines are least squared fits between the two
QHA methods and MD. For the lattice vec-
tors, there is marginal improvement in the
RMSD when using anisotropic expansion
(1.3%) over isotropic QHA (1.6%). There
is no improvement to RMSD for the lattice
angles (anisotropic 1.3%, isotropic 1.3%).
Despite there being little-to-no reduction
in the RMSD’s, the least square fit be-
tween anisotropic QHA and MD is similar
to the y = x line for both lattice vectors
and angles. This contrasts with isotropic
QHA, which is essentially independent of
MD box vectors, which is expected for the
fixed isotropic angles. Quantitatively, the
slopes for anisotropic and isotropic expan-
sion are 0.89±0.22 and 0.02±0.06 for the
box vectors (a, b, and c) and 0.60±0.14 and
0.0 (exactly) for the box angles (α, β and
γ), indicating that while anisotropic expan-
sion may over or undershoot the changes,
the directions of change are generally being
properly predicted.
Anisotropic expansion provides minimal
improvement in the error of polymorph free
energy differences between QHA and MD.
In Figure 8a we plot the Gibbs free energy
differences of both QHA methods against
the results for MD at Tmax. The RMSD of
∆G for isotropic and anisotropic QHA rel-
ative to MD are 0.113 and 0.079 kcal/mol,
respectively. There is only a 0.034 kcal/mol
improvement to the RMSD when using
an anisotropic thermal expansion model,
which is comparable to the bootstrapped
error in the RMSD. Anisotropic QHA in
18
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Figure 8: a) Gibbs free energy differences between polymorphs for QHA relative to MD and
b) entropy–enthalpy compensation in errors of QHA relative of MD. a) Overall, there is a
slight improvement of RMSD in the Gibbs free energy when using anisotropic expansion
over isotropic expansion. This improvement is only slightly larger than the bootstrapped
error in the RMSD. b) Grey shaded area indicates free energy differences < 0.12 kcal/mol
between QHA and MD, which for most of the graph indicates significant entropy–enthalpy
compensation. The only molecule to fall outside of these bounds for anisotropic QHA is
tolbutamide, which has the largest error in QHA relative to MD. In all plots, the filled-in
markers are the molecules with multiple molecular conformers (tolbutamide, chlorpropamide,
and aripiprazole).
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fact has a larger deviation from MD than
isotropic QHA for 3 of the 10 molecules,
though the deviation from MD is small.
Those molecules and their deviation of
anisotropic QHA from MD (δ(∆G1D)MD)
are pyrazinamide (0.037 kcal/mol), resorci-
nol (0.062 kcal/mol), and chlorpropamide
(0.033 kcal/mol). These results demon-
strate that the deviations in the free energy
differences between MD and QHA are due
to something other than an insufficiently ac-
curate thermal expansion model. Summary
results for each molecule is provided in the
Figure S57.
The difference between QHA and MD
is minimized when a lattice minimum cor-
responding the sampled MD lattice pa-
rameters and anisotropic QHA is used.
The largest errors for anisotropic QHA is
seen for tolbutamide (δ(∆G1D)MD = 0.206
kcal/mol), paracetamol (0.088 kcal/mol),
and resorcinol (0.062 kcal/mol) with all
other molecules < 0.045 kcal/mol. Under
the condition that a more consistent min-
imum with MD is used, we no longer find
that the error in QHA trends with molec-
ular size and flexibility.24 However, molec-
ular size and flexibility are correlated with
a greater number of alternative lattice min-
ima.58 We also see no correlation between
the error in QHA and the number of hydro-
gen bonds in the crystal (R2 < 0.1 in Figure
S67 and Figure S68). Tolbutamide form II
has a Z′ of 4 and all other polymorphs are
≤ 2, while this is not statistically significant
it could explain why the error in QHA is an
outlier. We also compared the gas and crys-
tal phase torsions, but found no differences
that distinguish tolbutamide from the rest
of the molecules (Torsions shown in figures
S60–S66).
We see entropy–enthalpy compensation
in the differences between anisotropic QHA
and MD of up to 0.12 kcal/mol for all
molecules except for tolbutamide. Despite
the entropy and enthalpy for QHA having
errors up to 0.5 kcal/mol from MD, the can-
cellation of those errors allows QHA to give
free energy differences within 0.09 kcal/mol
of the MD-calculated free energy differences
for all systems except tolbutamide. In Fig-
ure 8b the error in the entropic differences of
polymorphs is plotted versus the error in en-
thalpic differences of QHA relative to MD.
We define a set of polymorphs demonstrat-
ing entropy–enthalpy compensation (gray
shaded area) if the differences between er-
rors in entropy and enthalpy (i.e. the er-
ror in the free energy difference) is < 0.12
kcal/mol, giving us 90% confidence that a
re-ranking in crystal stability would not oc-
cur due to this error.24 Anharmonic mo-
tions may be important for computing the
enthalpy and entropy differences of poly-
morphs, but for most of the systems studied
here the error is minimal for computing the
free energy. The only molecule that falls
outside of this region for anisotropic QHA
is tolbutamide. Out of the 10 molecules, 8
have larger entropic error in QHA than en-
thalpic error, which is most likely due to
anharmonic motions. The only two sets
of polymorphs that have larger enthalpic
error in QHA are tolbutamide and chlor-
propamide, which are further explained in
the next section.
Molecular Conformational En-
sembles Can Still Exist Low
Temperatures
Even at low temperatures, some crystals
have substantial conformational degenera-
cies allowing quenched structures to settle
into lattice minima that break the symme-
try of the supercell. In figure 9b we show
frames of the trajectory of chlorpropamide,
with each frame taken 0.1 ns apart for the
last 5 ns of the 10 K ensemble produced
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Figure 9: Snapshots of the 10 K ensemble for chlorpropamide form a) I and b) V taken from
the last 5 ns of the replica exchange simulation, with 0.1 ns between each frame. Even at low
temperatures, this crystal structure samples a surprisingly diverse conformational ensemble,
with the greatest variability in the fluctuations around the alkyl tail. The RMSD of the
entire 10 K simulation ensemble relative to the lattice minimum for form I is 0.165 ± 0.02 A˚
and form V is 0.691 ± 0.21 A˚. c) Two frames of chlorpropamide form V that are 150 ps apart,
showing that the position of the terminal carbon is sampling two torsional conformations at
10 K. Graphical representation of a crystal with d) a single configurational minima and e)
multiple configurational minima drawn on a potential energy (U) against the configurational
space (x). f) Gibbs free energy difference of chlorpropamide form V relative to form I.
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during replica exchange. From this low
temperature ensemble, molecules are able
to sample a number of configurations due
to the degrees of freedom accessible to the
alkyl tail, and the low energy differences
between different alkyl rotamer configura-
tions. When quenched, the tails fall into
mostly independent conformations, break-
ing the crystal symmetry.
The thermodynamic accessibility of
many configurations at low temperatures is
a result of the existence of many configu-
rationally diverse lattice minima with sim-
ilar low energies. In Figure 9b the RMSF
of form V is 0.69 ± 0.21 A˚ at 10 K, which
is four times greater than form I where the
RMSF is 0.17 ± 0.02 A˚ (Figure 9a). The
more configurationally diverse behavior of
form V helps to explain why quenching the
MD simulations leads to so many different
lattice minima. Figure 9d provides a graph-
ical representation of the single lattice min-
imum and small configurational spaced cov-
ered at 10 K for form I, which contrasts with
Figure 9e representation of form V.
The number of accessible low-energy
minima causes a rapid deviation of QHA of
up to 0.06 kcal/mol in the free energy differ-
ence relative to MD for chlorpropamide as
low as 10 K. Figure 9f shows the polymorph
free energy differences for chlorpropamide
form V relative to form I for QHA and MD.
Based on the G(T ) plot from MD, between
0 and 10, the polymorph free energy differ-
ence for MD quickly changes, causing QHA
to diverge by 0.06 kcal/mol at 10 K. While
QHA can accurately model form I at low
temperatures, it cannot capture the behav-
ior of the alkyl tails in form V, which is
why we see the immediate divergence of the
two methods as T increases from zero. At
temperatures greater than 10 K the devia-
tion of the free energy from MD does not
grow because of the entropy–enthalpy com-
pensation, but we cannot necessarily con-
clude that this would be the case for other
crystals that could have alternate configura-
tional minimum. Both polymorphs of tolbu-
tamide also sample a large number of con-
formations at low temperatures, causing a
similar divergent behavior in ∆G for QHA
and MD at low temperatures (Figure S48).
The concavity in the free energy of chlor-
propamide at low temperatures is due to
dominating enthalpic changes close to 0 K,
which quickly diminish relative to the en-
tropic contributions as the temperature in-
creases. Surprisingly, although form V has
a larger low T configurational ensemble, it
initially becomes less stable as a function
of T relative to the more constrained form
I. Up to 10 K, form V expands faster than
form I (Figure 10a) causing an unfavorable
enthalpic contribution to form V relative to
form I (Figure 10b). Since T∆S is small
at low temperatures, the changes in the en-
thalpic difference dominates the free energy
differences. At temperatures greater than
10 K the difference in volume and enthalpy
between polymorphs is constant. The initial
expansion of form V allows the alkyl tails to
have more conformational space than form
I and by 20 K the entropic contributions in
form V are large enough to switch the sta-
bility of the polymorphs.
Conclusions
Although we have studied a relatively small
number of enantiotropic polymorphs in this
study, we find there here are persistent
shortcomings of QHA that highlight the
importance of anharmonic configurational
sampling in determining accurate free en-
ergy differences of crystal polymorphs. The
shortcomings identified in this study are:
1) that including anisotropic expansion pro-
vides minimal improvement in the error of
polymorph free energy differences between
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Figure 10: (a) Volume differences of chlorpropamide form V relative to form I using MD.
Initially, form V expands much faster than form I. Above 10 K, the difference in volume
between the forms is almost constant. (b) The entropic and enthalpic contributions to the
Gibbs free energy difference of chlorpropamide form V relative to I. Below 10 K, the potential
energy is the dominating free energy contribution making form V less favorable, explained
by the sudden expansion of form V seen at low temperatures.
QHA and MD, 2) the number of accessible
low-energy minima causes a rapid deviation
of QHA relative to MD for temperatures as
low as 10 K, 3) some crystals reorganize into
clearly different structures when heated up
to 300 K using MD, and 4) polymorph re-
structuring prevents QHA from being run
independently of MD because the minimum
energy configuration is likely to be inacces-
sible from an arbitrary low-energy starting
point.
We found that the OPLS-AA point
charge potential incorrectly ranked 4 of the
10 enthalpic differences of polymorphs rel-
ative to experiment, but correctly ranked
the entropic differences of all 10 molecules.
Despite the lattice geometries for MD dif-
fering moderately from experiment, the ex-
pansion of vectors and orthogonal angles for
MD generally agree with experiment. The
RMSD of both enthalpic and entropic dif-
ferences between MD and experiment were
4.0 and 2.0 kcal/mol, respectively, which is
roughly 2 orders of magnitude larger than
errors seen of QHA relative to MD if prop-
erly performed.
Our one-dimensional approach to model
anisotropic thermal expansion predicts es-
sentially identical high temperature lattice
geometries and polymorph free energy dif-
ferences as the full anisotropic QHA for the
10 polymorph pairs studied. Specifically,
the computed polymorph free energy differ-
ences are within 0.02 kcal/mol at Tmax for
our 1D- and fully-anisotropic QHA meth-
ods for the 10 molecules studied. The lat-
tice geometries of the two approaches re-
mained essentially the same, with an RMSD
of 0.29% for the expansion relative to lat-
tice minimum structure. Additionally, 1D-
anisotropic QHA is able to find a free energy
minimum up to 300 K for all but one crystal
unit cell, whereas the fully anisotropic ap-
proach fails to reach those desired temper-
atures for 50% of the crystals, due to the
larger likelihood of a rearrangement into an
alternate minimum when multiple deriva-
tives are used, resulting in numerical insta-
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bility of the approach.
Finite size effects do not always can-
cel out for polymorph free energy differ-
ences; instead, differences between unit cells
and supercells can be up to 0.5 kcal/mol
and therefore must be accounted for when
attempting to accurately rank crystal sta-
bility. We found that this error is corre-
lated with the error in the lattice geometries
(R2 = 0.79), meaning they are reduced but
not eliminated if the high temperature lat-
tice geometries are the same between unit
and supercells.
Anisotropic QHA only marginally im-
proves the error in free energy differences
from MD for the polymorph pairs studied.
Using anisotropic QHA reduces the RMSD
of ∆G relative to MD by 0.034 kcal/mol,
which is only slightly larger than the stan-
dard error in the RMSD. The errors in
QHA with respect to MD are due primarily
to anharmonic motions, because using an
anisotropic thermal expansion model does
not improve the deviations between QHA
and MD. Differences between anisotropic
QHA and MD do not appear strongly cor-
related with molecular flexibility. Tolbu-
tamide with both a large deviation and
high flexibility is an exception, and this
difference could also be due to the large
Z′ value of 4 for form II. The free energy
difference in tolbutamide had an error of
0.21 kcal/mol between anisotropic QHA and
MD, whereas all other molecules deviated
< 0.09 kcal/mol.
The degree of flexibility of the molecules
can result in a more significant chance
of crystal restructuring upon annealing
with replica exchange. Once a lower en-
ergy lattice minimum was found, the er-
ror in isotropic QHA was on average 0.08
kcal/mol lower than previously reported.24
Anisotropic QHA from the new minimum
was able to reduce the free energy differ-
ences between chlorpropamide and aripipra-
zole to < 0.05 kcal/mol. We were consis-
tently able to find lower lattice minimum
than those quenched directly from exper-
iment for more flexible molecules by run-
ning replica exchange molecular dynamics
and quenching frames from the low temper-
ature replica.
The polymorphs of conformationally
flexible molecules exhibit differences in ∆G
of QHA relative to MD on the magnitude of
0.06 kcal/mol even as low as 10 K, despite
the 0 K lattice energies being within 0.01
kcal/mol at 0 K, showing that agreement
between QHA and MD cannot be assumed
even at very low temperatures. These dif-
ferences are due to either one or both of the
polymorphs expanding quickly at low tem-
peratures, which the provides enough free
volume to access a diverse number of confor-
mations around the alkyl tail. We note that
the temperature at which a crystal can ac-
cess these conformations is structure depen-
dent, as seen with the different polymorphs
of chlorpropamide.
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Systems Studied
In Table 3 we provide the systems stud-
ied, their polymorphs names/numberings,
and corresponding Cambridge Structure
Database reference code (CSD Refcode),
and the dimensions of the unit and super-
cells relative to the symmetric cell pulled
from the database. The supercell sizes are
the same as our previous study and the unit
cells are the smaller cell size that assures
that both crystals have the same number of
molecules.
Piracetam Form I Form III
CSD Refcode BISMEV03 BISMEV02
Space Group P21/n P21/n
Z / Z′ 4/1 4/1
Unit cell Dimensions 1× 1× 1 1× 1× 1
Supercell Dimensions 4× 2× 3 2× 3× 4
Carbamazepine Form I Form III
CSD Refcode CBMZPN11 CBMZPN02
Space Group P1¯ P21/n
Z / Z′ 8/2 4/1
Unit cell Dimensions 1× 1× 1 2× 1× 1
Supercell Dimensions 4× 2× 1 4× 2× 2
Adenine Form I Form II
CSD Refcode KOBFUD KOBFUD01
Space Group P21/c Fdd2
Z / Z′ 8/2 16/1
Unit cell Dimensions 1× 1× 2 1× 1× 1
Supercell Dimensions 3× 1× 4 3× 1× 2
Pyrazinamide Form γ Form δ
CSD Refcode PYRZIN20 PYRZIN16
Space Group Pc P1¯
Z / Z′ 2/1 2/1
Unit cell Dimensions 1× 2× 1 2× 1× 1
Supercell Dimensions 4× 6× 2 4× 3× 4
Resorcinol Form α Form β
CSD Refcode RESORA03 RESORA08
Space Group Pna21 Pna21
Z / Z′ 4/1 4/1
Unit cell Dimensions 1× 1× 1 1× 1× 1
25
Supercell Dimensions 2× 2× 4 2× 2× 4
1,4-Diiodobenzene Form α Form β
CSD Refcode ZZZPRO03 ZZZPRO04
Space Group Pbca Pccn
Z / Z′ 4/1 4/1
Unit cell Dimensions 1× 1× 1 1× 1× 1
Supercell Dimensions 2× 3× 3 2× 3× 3
Paracetamol Form I Form II
CSD Refcode HXACAN01 HXACAN
Space Group P21/a Pcab
Z / Z′ 4/1 8/1
Unit cell Dimensions 1× 2× 1 1× 1× 1
Supercell Dimensions 2× 2× 3 2× 1× 3
Aripiprazole Form I Form X
CSD Refcode MELFIT01 MELFIT05
Space Group P21 P21
Z / Z′ 2/1 2/1
Unit cell Dimensions 1× 1× 1 1× 1× 1
Supercell Dimensions 3× 4× 2 3× 4× 2
Tolbutamide Form I Form II
CSD Refcode ZZZPUS04 ZZZPUS05
Space Group Pna21 Pc
Z / Z′ 4/1 8/4
Unit cell Dimensions 1× 2× 1 1× 1× 1
Supercell Dimensions 2× 3× 2 3× 2× 1
Chlorpropamide Form I Form V
CSD Refcode BEDMIG BEDMIG04
Space Group P212121 Pna21
Z / Z′ 4/1 4/1
Unit cell Dimensions 1× 1× 1 1× 1× 1
Supercell Dimensions 1× 4× 2 1× 4× 2
Table 3: Table of systems studied in the main paper. We have included the polymorph
names, CSD reference codes, and the cell dimensions relative to the symmetric unit cell
pulled down from the database.
1D vs. Full Anisotropic
QHA
In Table 4 we report the free energy differ-
ences of the unit cell of each system using
1D and fully anisotropic QHA at the max-
imum temperature that all methods could
achieve Tmax. We also report the deviation
between the two methods (δ(|∆G(Tmax)|))
in the far right column, which shows that
both methods are within 0.02 kcal/mol of
each other for all systems except for chlor-
propamide.
Differences in ∆G of the anisotropic
methods are correlated with the errors in
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Table 4: Free energy differences for 1D and fully anisotropic QHA at Tmax for the unit cells.
Tmax is the maximum temperature that both crystals and both methods can reach while still
being at a free energy minimum. For all systems there is < 0.02 kcal/mol difference in ∆G
with aripiprazole having the largest difference of 0.016 kcal/mol.
∆G(Tmax) [kcal/mol] δ(|∆G(Tmax)|)
System Tmax [K] 1D-QHA Aniso.-QHA
Piracetam 255 -1.374 -1.384 0.010
Carbamazepine 300 -0.160 -0.157 0.003
Adenine 300 1.330 1.328 0.002
Pyrazinamide 180 -0.552 -0.551 0.001
Resorcinol 300 -0.578 -0.578 0.000
1,4-Diiodobenzene 210 0.431 0.431 0.000
Paracetamol 150 -0.648 -0.652 0.004
Aripiprazole 180 -0.696 -0.712 0.016
Tolbutamide 100 -3.592 -3.593 0.001
Chlorpropamide 150 4.830 4.824 0.006
the predicted high temperature lattice ge-
ometries. Figure 11 has the absolute free
energy deviations between 1D- and fully-
anisotropic QHA versus the root-mean-
square deviation (RMSD) between Tmax lat-
tice geometries for individual polymorph.
The RMSD is computed as:
RMSD =
√√√√1
6
6∑
i=1
(C1Di (Tmax)− CFulli (Tmax))(10)
where the RMSD is taken between the six
lattice parameters of the upper triangular
crystal tensor form. From Figure 5c, we
can see that as the RMSD between the
1D- and fully-anisotropic Tmax structure be-
comes larger, so does the error in the com-
puted free energy of the polymorph. The
error in thermal expansion and free energy
for isotropic QHA is reduced by using the
1D-QHA variant. The differences in the free
energy are a direct result of the crystal ex-
panding to a slightly different geometry, but
we can see that this has little effect on the
free energy differences.
The 1D-variant reduces the error of the
isotropic QHA up to 90% for the sys-
tems studied relative to the fully anisotropic
approach. The deviations between 1D-
QHA and fully ansiotropic QHA are < 0.02
kcal/mol, whereas the error for isotropic
QHA is as large as 0.21 kcal/mol for indi-
vidual polymorphs (Figure 11). The largest
deviations in free energy for isotropic ex-
pansion come from aripiprazole form X and
chlorpropamide form V. The largest devi-
ation in free energy for 1D-QHA (0.0167
kcal/mol) is from aripiprazole form X.
Unit vs. Supercell 1D-
QHA
In Table 5 we report the free energy differ-
ences of the unit and supercell of each sys-
tem using 1D-QHA at the maximum tem-
perature all cell sizes could achieve Tmax.
We also report the deviation between the
two cell sizes (δ(|∆G(Tmax)|)) in the far
right column. We see that there are sig-
nificant finite size errors for all crystals that
range between 0.03 – 0.50 kcal/mol.
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Figure 11: Deviations in the free energy of the constrained QHA (isotropic QHA and 1D-
QHA) from anisotropic QHA versus the box vector RMSD from the unconstrained QHA
structure. All values are reported at Tmax. For individual free energies the 1D-variant devi-
ates < 0.02 kcal/mol, which is 10 times more precise than isotropic QHA that deviates up
to 0.21 kcal/mol from the fully anisotropic approach. Filled in markers are the systems with
multiple molecular conformers (tolbutamide, chlorpropamide, and aripiprazole).
Table 5: Free energy differences for unit and supercells at Tmax using 1D-QHA are reported.
Tmax is the maximum temperature that both crystals and cell sizes can reach while still being
at a free energy minimum. We find that size errors on the magnitude of 0.03 – 0.5 kcal/mol
for polymorph free energy differences.
∆G(Tmax) [kcal/mol] δ(|∆G(Tmax)|)
System Tmax [K] Unit Super
Piracetam 300 -1.364 -1.457 0.093
Carbamazepine 300 -0.160 0.044 0.204
Adenine 300 1.330 1.603 0.273
Pyrazinamide 300 -0.756 -0.613 0.143
Resorcinol 300 -0.578 -0.439 0.139
1,4-Diiodobenzene 300 0.427 0.389 0.038
Paracetamol 300 -1.241 -0.767 0.474
Aripiprazole 300 -0.764 -0.950 0.186
Tolbutamide 180 -3.602 -3.489 0.113
Chlorpropamide 50 5.374 5.287 0.087
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For individual polymorphs, there is no
trend between the differences in free energy
and the RMSD in the percent expansion up
to Tmax for unit and supercells; the trends
only appear for polymorph differences. Fig-
ure 12 compares the absolute deviation in
free energy with the RMSD in the percent
expansion for unit and supercells. The er-
ror in free energy between unit and super
cells is between 0 – 3 kcal/mol and does not
correlate with the cells percent expansion at
Tmax.
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Figure 12: The deviation in the free energy
between unit and super cell is shown relative
to the RMSD in the percent expansion. For
individual polymorphs there is no correla-
tion between error in the free energy and the
error in the high temperature lattice geome-
tries. The filled in markers are the systems
with multiple molecular conformers (tolbu-
tamide, chlorpropamide, and aripiprazole)
The finite size errors do not correlate
with the ratio of number of molecules in
the unit and supercells. We have super
cells that have 6 – 24 times the number
of molecules in the unit cells. We would
expect the systems with similar number of
molecules in the unit cell and supercell to
have smaller deviations in the free energy,
but that is not the case. In Figure 13 the
free energy deviation between the unit and
supercell at 300 K is plotted against the ra-
tio of molecules in the super cell relative to
the unit cell. The greatest error is seen for
paracetamol, which is one of the systems
with the most similar unit and super cells.
There is no correlation between the finite
size error and ratio of number of molecules
(R2 = 0.109).
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Figure 13: Plotting the finite size errors at
Tmax versus the ratio of number of molecules
between the super- and unit cell.
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Re-structuring
Figure 14: Lattice minimum of chlor-
propamide form I from quenching the ex-
perimental structure (green), the struc-
ture used in our previous study (blue),24
quenched from a 10 K replica exchange sim-
ulation (red). The RMSD between all struc-
tures is < 0.0001 A˚.
Figure 15: Lattice minimum of chlor-
propamide form V from quenching the ex-
perimental structure (green), the struc-
ture used in our previous study (blue),24
quenched from a 10 K replica exchange
simulation (red). The RMSD between the
structure quenched from experiment and
from our previous paper relative to the min-
ima found from REMD are 1.26 and 1.07 A˚,
respectively.
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Figure 16: Lattice minimum of aripipra-
zole form I from quenching the experimen-
tal structure (green), the structure used in
our previous study (blue),24 quenched from
a 10 K replica exchange simulation (red).
The RMSD between the structure from our
previous paper relative to the minima found
from REMD is 0.36 A˚.
Figure 17: Lattice minimum of aripipra-
zole form X from quenching the experimen-
tal structure (green), the structure used in
our previous study (blue),24 quenched from
a 10 K replica exchange simulation (red).
The RMSD between the structure from our
previous paper relative to the minima found
from REMD is 0.51 A˚.
Figure 18: Lattice minimum of tolbutamide
form I from quenching the experimental
structure (green), the structure used in our
previous study (blue),24 quenched from a
10 K replica exchange simulation (red).
The RMSD between the structure quenched
from experiment and from our previous
paper relative to the minima found from
REMD are 1.48 and 1.09 A˚, respectively.
Figure 19: Lattice minimum of tolbutamide
form I from quenching the experimental
structure (green), the structure used in our
previous study (blue),24 quenched from a
10 K replica exchange simulation (red).
The RMSD between the structure quenched
from experiment and from our previous
paper relative to the minima found from
REMD are 1.35 and 1.35 A˚, respectively.
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Free Energy Differences
and Expansion with Tem-
perature
The original MD data for several systems
were run with constraints that prevented
the angles from changing. While there fluc-
tuations in the angles should have been con-
sidered, the angles remain 90°across the en-
tire temperature range. For the following
systems the MD angles were fixed at 90°:
adenine from II, resorcinol from α and β,
diiodobenzene form α and β-restructured,
and paracetamol form II. For all crystals
where the angles are fixed at 90°, we ran
1 ns simulations at 50, 100, 200, and 300
K with the angles unfixed and verified that
average value of the angle remains at 90°.
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Figure 20: Polymorph free energy differences of piracetam form I relative to form III
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Figure 21: Piracetam form I percent expansion from 0 K with experimental results.59,60
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Figure 22: Piracetam form III percent expansion from 0 with experimental results.61–65
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Carbamazepine
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Figure 23: Polymorph free energy differences of carbamazepine form I relative to form III
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Figure 24: Carbamazepine form I percent expansion from 0 K with experimental results.66
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Figure 25: Carbamazepine form III percent expansion from 0 K with experimental re-
sults.47,49–53
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Adenine
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Figure 26: Polymorph free energy differences of adenine form II relative to form I
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Figure 27: Adenine from I percent expansion from 0 K with experimental results.67
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Figure 28: Adenine form II percent expansion from 0 K with experimental results.16
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Pyrazinamide
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Figure 29: Polymorph free energy differences of pyrazinamide form γ relative to form δ
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Figure 30: Pyrazinamide form γ percent expansion from 0 K with experimental results.68,69
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Figure 31: Pyrazinamide form δ percent expansion from 0 K with experimental results.14,70–72
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Resorcinol
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Figure 32: Polymorph free energy differences of carbamazepine form β relative to form α
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Figure 33: Resorcinol form α percent expansion from 0 K with experimental results.73–77
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Figure 34: Resorcinol form β percent expansion from 0 K with experimental results.74,75,77
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1,4-Diiodobenzene
For MD, form β was found to restructure
at high temperature to form β-restructured.
We show the results for form β using
QHA only, where the lattice minimum was
found by directly quenching the experimen-
tal crystal structure. The results for form β
were used for the comparison of the 1D vari-
ant and fully anisotropic QHA, as well as
the error with cell size. Form β-restructured
was used for the comparison to MD.
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Figure 35: Polymorph free energy differences of diiodobenzene form β-restructured relative
to form α
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Figure 36: Diiodobenzene form α percent expansion from 0 K with experimental re-
sults.17,78,79
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Figure 37: Diiodobenzene form β percent expansion from 0 K with experimental results.
MD is not shown for the original structure of β because the system restructured at high
temperature.
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Figure 38: Diiodobenzene form β-restructured percent expansion from 0 K with experimental
results.
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Paracetamol
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Figure 39: Polymorph free energy differences of paracetamol form I relative to form II
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Figure 40: Paracetamol form I percent expansion from 0 K with experimental results.48,54–56
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Figure 41: Paracetamol form II percent expansion from 0 K with experimental results.80–82
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Aripiprazole
For MD, both crystal structures were
found to restructure at high temperature to
form. We show the results for for I and X
using QHA only, where the lattice minimum
was found by directly quenching the experi-
mental crystal structure. These results were
used for the comparison of the 1D variant
and fully anisotropic QHA, as well as the
error with cell size. Form I-restructured and
form X-restructured were used for the com-
parison to MD.
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Figure 42: Aripiprazole form I percent expansion from 0 K. MD is not shown for the original
structure of I because the system restructured at high temperature.
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Figure 43: Aripiprazole form X percent expansion from 0 K. MD is not shown for the original
structure of X because the system restructured at high temperature.
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Figure 44: Polymorph free energy differences of aripiprazole form X-restructured relative to
form I-restructured
48
0 100 200 300
7.6
7.8
8.0
8.2
8.4
8.6
8.8
La
tti
ce
 V
ec
to
r [
Å]
a-Vector
Iso. QHA 1D-QHA MD Braun 2009
0 100 200 300
7.50
7.55
7.60
7.65
7.70
7.75
b-Vector
0 100 200 300
17
18
19
20
c-Vector
0 100 200 300
89.00
89.25
89.50
89.75
90.00
90.25
90.50
90.75
91.00
An
gl
e 
[D
eg
.]
-Angle
0 100 200 300
93
94
95
96
97
-Angle
0 100 200 300
89.00
89.25
89.50
89.75
90.00
90.25
90.50
90.75
91.00
-Angle
0 100 200 300
Temperature [K]
1110
1120
1130
1140
1150
1160
1170
1180
1190
Vo
lu
m
e 
[Å
3 ]
Temperature [K]
Figure 45: Aripiprazole form X-restructured percent expansion from 0 K with experimental
results.44
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Figure 46: Aripiprazole form I-restructured percent expansion from 0 K with experimental
results.44
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Tolbutamide
For MD, form I was found to restructure
at high temperature to form I-restructured.
We show the results for form I using
QHA only, where the lattice minimum was
found by directly quenching the experimen-
tal crystal structure. The results for form I
were used for the comparison of the 1D vari-
ant and fully anisotropic QHA, as well as
the error with cell size. Form I-restructured
was used for the comparison to MD.
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Figure 47: Tolbutamide form I percent expansion from 0 K.MD is not shown for the original
structure of I because the system restructured at high temperature.
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Figure 48: Polymorph free energy differences of tolbutamide form II relative to form I-
restructured.
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Figure 49: Tolbutamide form I-restructured percent expansion from 0 K with experimental
results.83–86
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Figure 50: Tolbutamide form II percent expansion from 0 K with experimental results.43,84,86
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Figure 51: Tolbutamide form II-restructured percent expansion from 0 K with experimental
results.43,84,86
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Chlorpropamide
For MD, form V was found to re-
structure at high temperature to form V-
restructured. We show the results for form
V using QHA only, where the lattice min-
imum was found by directly quenching the
experimental crystal structure. The results
for form V were used for the comparison of
the 1D variant and fully anisotropic QHA,
as well as the error with cell size. Form V-
restructured was used for the comparison to
MD.
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Figure 52: Polymorph free energy differences of chlorpropamide form V-restructured relative
to form I-Restructured
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Figure 53: Chlorpropamide form I percent expansion from 0 K with experimental results.87,88
MD is not shown here because this is QHA using the minima directly quenched from the
experimental structure, which does not correspond with the 0 K minima found with MD.
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Figure 54: Chlorpropamide form I-Restructured percent expansion from 0 K with experi-
mental results.87,88
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Figure 55: Chlorpropamide form V percent expansion from 0 K. MD is not shown here
because this is QHA using the minima directly quenched from the experimental structure,
which does not correspond with the 0 K minima found with MD.
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Figure 56: Chlorpropamide form V-restructured percent expansion from 0 K with experi-
mental results.87,89
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Summary of Results
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Figure 57: Deviations in the free energy differences from MD at 300 K (except for tolbutamide
at 200 K, and chlorpropamide at 250 K). We report results for isotropic QHA and 1D-
anisotropic QHA relative to MD. Overall, there is no evidence that a more complex thermal
expansion model reduces the error between QHA and MD.
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Figure 58: Deviations in the entropic contribution to the Gibbs free energy differences from
MD at 300 K (except for tolbutamide at 200 K, and chlorpropamide at 250 K). We report
results for isotropic QHA and 1D-anisotropic QHA relative to MD. The entropy differences
between methods are compensated by a larger enthalpy difference, resulting in a smaller free
energy differences.
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Figure 59: Deviations in the enthalpic contribution to the Gibbs free energy differences from
MD at 300 K (except for tolbutamide at 200 K, and chlorpropamide at 250 K). We report
results for isotropic QHA and 1D-anisotropic QHA relative to MD. The enthalpy differences
between methods are compensated by a larger enthalpy difference, resulting in a smaller free
energy differences.
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Replica Exchange
System Simulation Time [ns] Temperatures Sampled [K]
Aripiprazole 20 10.0, 10.2, 10.4, 10.6, 10.8, 11.0, 11.2, 11.5,
11.8, 12.1, 12.4, 12.7, 13.0, 13.3, 13.6, 13.9,
14.2, 14.6, 15.0, 15.4, 15.8, 16.2, 16.6, 17.0,
17.4, 17.9, 18.4, 18.9, 19.4, 19.9, 20.4, 21.0,
21.6, 22.2, 22.8, 23.4, 24.1, 24.8, 25.5, 26.2,
27.0, 27.8, 28.6, 29.4, 30.3, 31.2, 32.1, 33.1,
34.1, 35.1, 36.2, 37.3, 38.4, 39.6, 40.8, 42.0,
43.3, 44.6, 46.0, 47.4, 48.9, 50.4, 52.0, 53.6,
55.3, 57.0, 58.8, 60.7, 62.6, 64.6, 66.6, 68.7,
70.9, 73.2, 75.5, 77.9, 80.4, 81.1, 83.0, 85.7,
88.5, 91.4, 94.4, 97.5, 100.7, 104.0, 107.4,
110.9, 114.5, 118.2, 122.1, 126.1, 130.2, 134.5,
138.9, 143.5, 148.2, 153.1, 158.1, 163.3, 168.7,
174.3, 179.1, 180.0, 185.9, 188.1, 192.0, 200.0,
204.9, 211.7, 218.7, 225.9, 233.4, 241.1, 249.1,
257.4, 265.9, 274.7, 283.8, 293.2, 302.9, 313.0,
323.4, 334.2, 345.3, 350.0
Tolbutamide 20 10.0, 10.30, 10.6, 10.9, 11.2, 11.5, 11.8, 12.1,
12.5, 12.9, 13.3, 13.7, 14.1, 14.5, 15.0, 15.5,
16.0, 16.5, 17.0, 17.6, 18.2, 18.8, 19.4, 20.1,
20.8, 21.5, 22.3, 23.1, 23.9, 24.8, 25.7, 26.6,
27.6, 28.6, 29.7, 30.8, 31.9, 33.1, 34.3, 35.6,
36.9, 38.3, 39.8, 41.3, 42.9, 44.6, 46.3, 48.1,
50.0, 52.0, 54.0, 56.1, 58.3, 60.6, 63.0, 65.5,
68.1, 70.8, 73.6, 76.6, 79.7, 82.9, 86.2, 89.7,
93.3, 97.1, 101.0, 105.1, 109.4, 113.9, 118.6,
123.4, 128.5, 133.8, 139.3, 145.0, 151.0, 157.2,
163.7, 170.5, 177.5, 184.8, 192.4, 200.0, 208.7,
217.3, 226.3, 235.7, 245.5, 255.7, 266.3, 277.4,
288.9, 300.9, 313.4, 326.5, 340.1, 350.0
58
Chlorpropamide 30 3.00, 3.12, 3.25, 3.38, 3.52, 3.67, 3.83, 4.00,
4.18, 4.37, 4.57, 4.78, 5.00, 5.24, 5.49, 5.75,
6.03, 6.32, 6.63, 6.96, 7.31, 7.68, 8.07, 8.48,
8.92, 9.38, 9.87, 10.39, 10.94, 11.52, 12.13,
12.78, 13.46, 14.10, 14.18, 14.94, 15.75, 16.20,
16.60, 17.50, 18.46, 19.47, 20.54, 21.67, 22.87,
24.14, 25.48, 26.9, 28.4, 29.98, 31.65, 33.42,
35.29, 37.27, 39.36, 41.58, 43.92, 45.80, 46.40,
49.02, 51.79, 54.72, 57.82, 61.10, 64.57, 67.30,
68.24, 72.12, 74.80, 75.10, 76.22, 80.56, 85.15,
90.00, 95.13, 100.56, 106.30, 112.37, 118.79,
125.58, 132.76, 140.36, 148.39, 156.89,
160.90, 165.88, 175.38, 183.60, 185.43,
187.90, 194.40, 196.06, 200.00, 205.30,
207.30, 219.19, 231.76, 245.06, 253.20,
259.13, 274.01, 289.74, 305.70, 306.38,
323.98, 332.20, 333.50, 342.59, 362.27,
382.20, 383.09, 390.70, 400.00
Table 6: Systems that replica exchange we run on, the amount of time run for, and the
temperatures used for exchange. Chlorpropamide was run to lower temperatures to validate
our findings at low temperatures and therefore required 10 ns longer of simulation time for
these low temperatures to converge conformationally.
Comparison of Gas &
Crystal Torsions
For all molecules that contain 1 or more free
rotating torsions, we compared the torsional
distributions in the gas state with the crys-
tals at 300 K. The gas states were run with
REMD from 300 to 1000 K with about 0.2
probability exchange between replica.
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Figure 60: Torsional distributions of piracetam at 300 K for the molecule in gas and both
polymorphs.
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Figure 61: Torsional distributions of carbamazepine at 300 K for the molecule in gas and
both polymorphs.
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Figure 62: Torsional distributions of paracetamol at 300 K for the molecule in gas and both
polymorphs.
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Figure 63: Torsional distributions of chlorpropamide at 300 K for the molecule in gas and
both polymorphs.
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Figure 64: Torsional distributions of aripiprazole at 300 K for the molecule in gas and both
polymorphs for torsions 1 – 5.
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Figure 65: Torsional distributions of aripiprazole at 300 K for the molecule in gas and both
polymorphs for torsions 6 – 10.
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Figure 66: Torsional distributions of tolbutamide at 300 K for the molecule in gas and both
polymorphs.
Error in QHA due to Hy-
drogen Bonds
We found that there was little to no cor-
relation between the hydrogen bonds and
the error in anisotropic QHA relative to
MD. We determine the number of hydro-
gen bonds on a per molecule basis for the
lattice minimum (Figure 67) and the per-
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cent of hydrogen bonds remaining at 300 K
(Figure 68) for MD for all systems to see
if there was any correlation between error
in 1D-QHA from MD (δ(∆GQHA)) and the
number of hydrogen bonds. Despite hav-
ing no hydrogen bonds present, diiodoben-
zne has the lowest error in the QHA free en-
ergy difference and we therefore left it out
of both Figure 67 and 68. In both cases, a
linear fit shows the R2 value is less than 0.1
showing that there is little to no correlation.
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Figure 67: Error in the polymorph free en-
ergy differences for 1D-QHA from MD ver-
sus the number of hydrogen bonds in the
lattice minimum structure. There is no cor-
relation between QHA error and 0 K hydro-
gen bonds.
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Figure 68: Error in the polymorph free en-
ergy differences for 1D-QHA from MD ver-
sus the percent of hydrogen bonds remain-
ing at 300 K relative to the lattice minimum.
There is no correlation between QHA error
and 300 K hydrogen bonds.
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